Vectibix® (panitumumab)
- December 13, 2020
- 0
Vectibix®
Panitumumab
Chemotherapy
Vectibix®
Panitumumab
Chemotherapy
What is VECTIBIX?
Vectibix is indicated as a single agent for the treatment of epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
What is the most important information I should know about VECTIBIX?
- Increased Toxicity With Combination Chemotherapy: Vectibix is not indicated for use in combination with chemotherapy. In an interim analysis of Study 2, the addition of Vectibix to the combination of bevacizumab and chemotherapy resulted in decreased overall survival and increased incidence
- Patients to contact a healthcare professional for any of the following:
- Skin and ocular/visual changes
- Signs and symptoms of infusion reactions including fever, chills, or breathing problems
- Persistent or recurrent coughing, wheezing, dyspnea, or new onset facial swelling
- Pregnancy or nursing
- Patients of the need for:
- Periodic monitoring of electrolytes
- Limitation of sun exposure (use sunscreen, wear hats) while receiving Vectibix and for 2 months after the last dose of Vectibix therapy
- Adequate contraception in both males and females while receiving Vectibix and for 6 months after the last dose of Vectibix therapy
How should I take VECTIBIX?
- Your healthcare provider will prescribe the dose of VECTIBIX that is right for you.
- Take VECTIBIX exactly as your healthcare provider tells you.
